Sarcomas

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

R. Lor Randall, MD, FACS, discusses the challenges associated with incorporating surgical protocols into clinical trials evaluating sarcoma treatments.

Eric Nadler, MD, MPP, discusses the inherent complexity of diagnosing sarcomas.

R. Lor Randall, MD, FACS, discusses future research directions for advancing prosthetic embodiment for patients with sarcoma undergoing amputation.

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

Palbociclib hit the primary end point of disease control in a phase 2 study of patients with advanced chordoma harboring p16 and/or CDKN2A loss.

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.

The European Commission approved nirogacestat for the treatment of progressing desmoid tumors requiring systemic treatment.

PLD plus ifosfamide produced an ORR of 33% and a DCR of 83% in advanced soft tissue sarcoma, with manageable toxicity.

Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.

The first-in-class, allogeneic stem cell–loaded oncolytic virus CLD-201 was granted FDA fast track designation for the treatment of soft tissue sarcoma.

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.